



Press release

## Stef Heylen is the new head of Janssen Pharmaceutica

**Beerse, 2 November 2016 – Johnson & Johnson has announced today that Stef Heylen will be the new head of Janssen Pharmaceutica. He will succeed Tom Heyman, who has led the company successfully for eight years. Tom Heyman will still be active within Johnson & Johnson.**

From 3 November, Stef Heylen will take over from Tom Heyman as head of Janssen Pharmaceutica. Officially, he will be given the positions of managing director and chairman of the management committee of Janssen Pharmaceutica N.V. (Ltd.). Stef Heylen is also chief operating officer of Janssen R&D and will combine that position in the future with his new position of managing director of Janssen Pharmaceutica. Tom Heyman will still be active within Johnson & Johnson and will work full time in his position of global head of the Johnson & Johnson development corporation (JJDC). Tom will also still be the chairman of the Janssen Pharmaceutica N.V. executive board.

### **About Janssen, the pharmaceutical companies of Johnson & Johnson**

Johnson & Johnson is one of the biggest and most versatile companies in the world in the field of health care. The Pharmaceutical Group of Johnson & Johnson operates worldwide under the name of Janssen, the pharmaceutical companies of Johnson & Johnson and is now one of the most progressive pharmaceutical companies in the world. The group is a pioneer in therapeutic fields such as oncology, immunology, neurosciences, infectious diseases & vaccines, and cardiovascular & metabolic complaints.

### **About Janssen Pharmaceutica**

One of the most prominent Janssen companies is the Belgian Janssen Pharmaceutica. Janssen has offices in Belgium in Beerse (Beerse I and II), Geel, Olen, La Louvière, and Merksem and employs a total of about 4800 people. Together, the offices in Belgium discover, develop, and produce medicines and therapeutic solutions for patients all over the world. This process starts at the very beginning and runs from the basic research and the development of new medicines over the production, commercial and support services, to the distribution of medicines inclusive. This means that Janssen in Belgium has control of the entire pharmaceutical cycle, something which makes the company unique in the pharmaceutical world.

### **For more information:**

Tim De Kegel  
(0473) 746028  
[tdkegel@its.jnj.com](mailto:tdkegel@its.jnj.com)  
[www.janssen.com/belgium](http://www.janssen.com/belgium)